Latest Breaking News On - Executive scientific director - Page 1 : comparemela.com

IMU Biosciences raises £11 5 million Series A

We are delighted to announce that Molten Ventures has led a £11.5 million Series A funding round in IMU Biosciences, a techbio company revolutionising immune powered precision medicine. IMU.

United statesCity ofUnited kingdomTim hainesOliver nussbaumerAdrian haydayMario canteroInga deakinAdam laingAdaptate biotherapeuticsTom haydayKing college londonDuke universityFrancis crick instituteNon executive chairExecutive partner

IMU Biosciences secures £11 5 million in Series A funding to revolutionise immune powered precision medicine

IMU Biosciences secures £11 5 million in Series A funding to revolutionise immune powered precision medicine
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofOliver nussbaumerFrazer hallLeila adlamInga deakinTim haines abingworthAdam laingTom haydayTim hainesMario canteroAdaptate biotherapeuticsEntrepreneur in residence at duke universityProfessor adrian hayday at king college londonHead of communicationsNon executive chair

Quest Launches Consumer-Initiated Genetic Test on questhealth com to Deliver Personalized, Actionable Health Risk Insights

First consumer genetic health test under the Quest brand provides insights based on DNA, with unique features that include next-generation sequencing, robust support services, physician ordering,.

United statesQuest diagnosticsQuest diagnostics incorporatedQuest consumer incGenetic insightsSarah southExecutive scientific directorMolecular geneticsGenetics insightsDiagnostics incorporatedAssociated hereditary breastOvarian cancer

Children Treated With Remestemcel-L Show Long-Term Survival

Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years.

United statesJoanne kurtzbergSilviu itescuSteve dabkowskiPatricia steinertPaul hughesMarrow transplant researchInternational bloodAustralian securities exchangeMarrow transplantation groupDuke university medical centerMesoblast limited nasdaqCorporate communications investorsDrug administrationNational marrow donor programInternational blood marrow

Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

23.11.2022 - Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children . Seite 1

United statesJoanne kurtzbergPatricia steinertDuke university medical centerMesoblast limited nasdaqMarrow transplant researchDrug administrationInternational bloodInternational blood marrowDepartment of medicine centerKey pointsBiologics license applicationUnited states foodJerome harrisDistinguished professorExecutive scientific director